Page last updated: 2024-08-24

irinotecan and Shock, Septic

irinotecan has been researched along with Shock, Septic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Gou, R; Horikawa, N; Inayama, Y; Ito, K; Kosaka, K; Nakatani, E; Tani, H; Tsuji, M; Umemiya, M; Yoshida, T; Yu, S	1
Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J	1
Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ	1

Trials

2 trial(s) available for irinotecan and Shock, Septic

Article	Year
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC cancer, 2004, Jul-16, Volume: 4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate	2004
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis	2008

Article

Year

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.

BMC cancer, 2004, Jul-16, Volume: 4

Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate

2004

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis

2008

Other Studies

1 other study(ies) available for irinotecan and Shock, Septic

Article	Year
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study. Drugs in R&D, 2022, Volume: 22, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Enterocolitis, Neutropenic; Female; Genital Neoplasms, Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Retrospective Studies; Risk Factors; Shock, Septic	2022